subscribeSubscribe
Ulipristal acetate for uterine fibroids: EMA recommends restricting use

Ulipristal acetate for uterine fibroids: EMA recommends restricting use
EMA
13 Nov 2020
Share Share
AbbVie withdraws uterine fibroids drug from Canada

AbbVie withdraws uterine fibroids drug from Canada
Trisha Roy REUTERS
01 Oct 2020
Share Share
AbbVie withdraws uterine fibroids drug from Canada

AbbVie withdraws uterine fibroids drug from Canada
REUTERS
30 Sep 2020
Share Share
Health Canada Issues Recall of Allergan Canada`s Fibristal 5MG

Health Canada Issues Recall of Allergan Canada`s Fibristal 5MG
HEALTH CANADA
24 Sep 2020
Share Share
Health Canada reviews safety of drug Fibristal following new liver injury

Health Canada reviews safety of drug Fibristal following new liver injury
HEALTHYCANADA
16 Sep 2020
Share Share
EMA safety recommends withdrawal of ulipristal acetate marketing authorisation

EMA safety recommends withdrawal of ulipristal acetate marketing authorisation
EU PHARMACEUTICALREVIEW
10 Sep 2020
Share Share
EMA’s PRA recommends revoking marketing authorisation of ulipristal acetate

EMA’s PRA recommends revoking marketing authorisation of ulipristal acetate
PHARMABIZ
06 Sep 2020
Share Share
EMA recommends pulling ulipristal acetate for fibroids

EMA recommends pulling ulipristal acetate for fibroids
Kari Oakes RAPS
04 Sep 2020
Share Share
Allergan, following years of turmoil and resistance, heads for split

Allergan, following years of turmoil and resistance, heads for split
Eric Sagonowsky FIERCE PHARMA
19 Jun 2019
Share Share
Myovant hits goal in uterine fibroid phase 3

Myovant hits goal in uterine fibroid phase 3
Nick Paul Taylor FIERCE BIOTECH
15 May 2019
Share Share